Using Biomarkers to Change our Approach to Early Clinical Development

Time: 9:30 am
day: Conference Day Two


  • Proof of concept studies (POC) today are time consuming, costly and deliver undifferentiated therapeutic options for patients mainly because current clinical endpoints lack dynamic range and carry imprecisions
  • Defining complementary molecularly based clinical endpoints with high dynamic ranges and very low intra- and inter-assessor variability would beneficially impact the duration of POC studies
  • Defining complementary molecular-based clinical endpoints would also allow a thorough comparison of existing and upcoming therapeutics in a disease area